Regeneron Pharmaceuticals, INC Form 4 insider transactions

Regeneron's EVP Commercial, Marion McCourt, reported the acquisition of restricted stock and stock options, as well as the disposition of shares to cover tax obligations.

Regeneron's EVP, General Counsel, and Secretary, Joseph LaRosa, reported the acquisition of restricted stock and stock options, as well as the disposal of shares to cover tax obligations.

Andrew Murphy, EVP of Research at Regeneron Pharmaceuticals, reports a gift of 1,185 common stock shares and updates to his beneficial ownership.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on November 1, 2024, under a pre-arranged 10b5-1 trading plan.

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. (REGN) on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold 1,000 shares of common stock on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Director George L. Sing reports gifting 1,200 shares of Regeneron Pharmaceuticals common stock.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold 1,000 shares of common stock on September 3, 2024, under a pre-arranged 10b5-1 trading plan.

Arthur F. Ryan, a director at Regeneron Pharmaceuticals, sold a portion of his holdings in common stock on September 3, 2024, under a pre-arranged trading plan.

Regeneron's CFO, Christopher R. Fenimore, executed multiple sales of company stock on August 28, 2024, at prices ranging from approximately $1,204.00 to $1,206.86.

Director Bonnie L. Bassler exercised stock options and sold shares of Regeneron Pharmaceuticals, Inc. on August 15, 2024, according to a Form 4 filing.

Director Christine Poon exercised stock options and sold shares of Regeneron Pharmaceuticals on August 15, 2024.

Regeneron's EVP of Research, Andrew Murphy, exercised stock options and sold shares of common stock on August 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Neil Stahl, EVP of Research and Development at Regeneron Pharmaceuticals, reported a gift of 500 shares of common stock.

Neil Stahl, EVP of Research and Development at Regeneron Pharmaceuticals, sold shares of common stock on August 8, 2024, and gifted shares on August 12, 2024.

Jason Pitofsky, VP Controller at Regeneron Pharmaceuticals, exercised stock options and sold shares on August 7, 2024.

Regeneron's EVP of Research and Development, Neil Stahl, exercised stock options and disposed of shares to cover tax obligations.

Bonnie L. Bassler, a director at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on August 2, 2024, under a pre-arranged 10b5-1 trading plan.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged 10b5-1 trading plan.

Director Arthur F. Ryan of Regeneron Pharmaceuticals, Inc. reported the sale of 1 share of common stock on August 1, 2024, according to a Form 4 filing with the SEC.

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. (REGN) on August 1, 2024, under a pre-arranged 10b5-1 trading plan.

Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,866 shares of common stock at a price of $1,088.95 per share on July 11, 2024, under a pre-arranged 10b5-1 trading plan.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on July 1, 2024, under a pre-arranged 10b5-1 trading plan.

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. on July 1, 2024, under a pre-arranged 10b5-1 trading plan.

Bonnie L. Bassler, a director at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on June 24, 2024, under a pre-arranged trading plan.

Regeneron's EVP, General Counsel, and Secretary, Joseph LaRosa, exercised stock options and disposed of shares to cover tax obligations.

Regeneron Pharmaceuticals Director Michael S. Brown exercised stock options and sold shares of common stock on June 14, 2024, under a pre-arranged 10b5-1 trading plan.

Regeneron's CEO, Leonard Schleifer, reports multiple transactions involving the sale and acquisition of company stock, including common stock and Class A stock, executed under a pre-arranged 10b5-1 trading plan.

George Yancopoulos, a top executive at Regeneron Pharmaceuticals, reported the transfer of company stock via gift and trust arrangements.

Joseph LaRosa, EVP General Counsel and Secretary of Regeneron Pharmaceuticals, reported a gift of 1,608 shares of common stock.